ORGAN ON CHIP IN DEVELOPMENT
The ORCHID project (Organ-on-Chip development) is an EU initiative, coordinated by Leiden University Medical Center and the Dutch Organ-on-Chip consortium hDMT in The Netherlands. The main goal of ORCHID is to create a roadmap for organ-on-chip technology and to build a network of all relevant stakeholders in this promising innovative field. In the ORCHID project that started on 1 October 2017 in total seven leading European research institutions are involved. The project is closed since 1 October 2019. here.
The final report can be downloaded here.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 766884
FINAL REPORT
The Horizon 2020 FET-Open project Organ-on-Chip In Development (ORCHID) is closed on October 1st 2019.
The final report on the achievements of ORCHID and information on how we will continue all the Organ-on-Chip can be downloaded here.
Project ORCHID: Organ-on-Chip In Development
Summary
Organ-on-chip technology will revolutionize the healthcare domain by offering new and ground breaking solutions to different industries and especially for regenerative medicine and medication. Organ-on-Chip In Development (ORCHID) will create a roadmap for organ-on-chip technology and the framework to build a network of relevant stakeholders. ORCHID will achieve this through 5 objectives:
- evaluation of the technology (state of the art and unmet needs)
- identification of ethical issues, establishing standards and identifying measures for regulatory implementation
- analysis of economic and societal impact, training and education
- developing a roadmap which will guide the required R&D efforts and
- raising awareness and building the ecosystem for organ-on-chip technology through a digital reference platform.
ORCHID will have a broad impact: it will facilitate drug development, contribute significantly to reducing animal experiments and help in developing personalized medicine. ORCHID will achieve these goals by providing a framework to the main stakeholders, bringing together key players and raising awareness on organ-on-chip technology throughout Europe. The digital platform will gather all information on existing and new initiatives in the field. In this way ORCHID as a whole will secure and reinforce Europe’s leadership on organ-on-chip. The consortium is composed of the main contributors to the field who are all very experienced and who will strongly collaborate with each other. Leiden University Medical Centrum (LUMC) will lead the consortium, the Institute for human Organ and Disease model (hDMT) will focus on the strategy and the roadmap, Fraunhofer IGB on impact assessment, CEA Leti on eco-system development and the digital platform, IMEC on the ethical aspects, regulation and standardization and the University of Zaragoza will lead dissemination. ORCHID will install an Advisory Board composed of complementary specialists in the field.
Organ-on-chip: a Future Emerging Technology
Organs-on-chips will radically change the way and the speed at which drugs can be implemented clinically, not only for general drug development but also for personalised drugs. This is not only key for making drug and cosmetic development test-animalfree, but the accuracy and speed with which outcomes can be evaluated will surpass standard cell cultures and laboratory animals that presently capture human physiology and response on drugs imperfectly.
Organ-on-chip technology is cutting-edge science, which goes beyond the frontiers of knowledge and requires multidisciplinary collaboration. hDMT, one of the partners of this consortium, has submitted a FET Flagship proposal for this technology with a broad support from European research centres and is actively working with other regenerative medicine proposals to settle a broad EU flagship. Partners are European leaders in their specialist area but their collaboration is essential to realize the potential of this emerging technology.
The main goal of this CSA is to create a roadmap for organ-on-chip technology and to build a network of academia, research institutes, industry, and regulatory bodies to move organ-on-chip technology from promise in the laboratory into reality for the citizens of the Europe and the rest of the world.
OBJECTIVES
1: Assess the status of organ-on-chip technology in Europe
Identify the state-of-the-art on organ-on-chip technology in Europe and worldwide and define the challenges in the field of
- Human cell technology (stem cells, organoids, primary tissue explants)
- Chip technology (microfluidics, microfabrication, micromanipulation)
- Steering and monitoring protocols, predictive model development and data analysis (automation, signal and image processing, big data analysis, computational modelling)
- Applications
- Identify the unmet needs which can be served by organ-on-chip technology and prioritize the applications that should be targeted, in particular for healthcare, personalized medicine, animal experimentations, and how to introduce organ-on-chip approaches for these particular applications.
2: Identify ethical issues, drive standardization and take steps for regulatory take-off
- Chart the available standards and regulatory network of laws, regulations and guidelines to take away potential barriers, and make recommendations to accelerate the uptake of organ-on-chip technologies.
- Assess ethical aspects of personalized organ-on-chip technology during the project and issue recommendations towards the policy makers.
3: Analyse the impact on economy, society, training and education
- Analyse the economic and societal impact of organ-on-chip technology, including the effect on the 3Rs guiding principle of reduction, refinement and replacement of animal experiments.
- Identify interdisciplinary skills and experiences necessary to prepare young scientists for the utilization of organ-on-a-chip technologies in their future careers.
4: Establish the organ-on-chip technology roadmap
- Develop the organ-on-chip roadmap, indicating technology gaps, identifying trans EU synergy opportunities, including policy recommendations for regulation, training and education to ensure a successful implementationers.
5: Raise awareness and build the ecosystem for organ-on-chip technology
- Promote the technology by defining and launching a digital platform which will become a worldwide reference for organ-on-chip technology in the coming years (2-4 years).
- Promote interest in organ-on-chip technology by defining and organizing specialized training and education for young researchers, to enhance competencies within Europe in this field.
- Organise and inform the value chain and stakeholders to raise awareness, build the ecosystem and maximise the benefits of this technology for economy and citizens health.
The indicators for these different objectives are:
- The roadmap for organ-on-chip technology and its applications, based on the development status and the impact: technology v2.0, next areas to be explored, definition of the intermediate milestones and objectives, etc.
- Training, education and exchange research programs to promote the technology including relevant skills.
- Installation of a large international ORCHID advisory board to advise and raise awareness on the technology.
- Digital platform which will be the reference for all stakeholders.
- List of activities to raise awareness about organ-on-chip technology: events/workshops involving stakeholders, media publicity (social media/general media), publications. Recommendations to pave the way for innovation: facilitate market introduction, preparing the regulation and legislation for the organ-on-chip technology, solving ethical issues.
Deliverables
Del. Number | Deliverable Title | WP Number | Lead | Type | Dissemination Level | Due date (M) | Delivered (dd/mm/yy) |
---|---|---|---|---|---|---|---|
D1.1 | Project handbook and quality assurance plan | WP1 | LUMC | Report | CO | M3 | 04/01/18 |
D1.2 | Inception report | WP1 | LUMC | Report | CO | M3 | 29/12/17 |
D1.3 | Technical report M12 | WP1 | LUMC | Report | CO | M13 | 31/10/18 |
D1.4 | Technical report M24 | WP1 | LUMC | Report | CO | M24 | 11/11/19 |
D2.1 | Methodology of the project | WP2 | hDMT | Report | CO | M3 | 29/12/17 |
D2.2 | State of the art on organ-on-chip technology | WP2 | hDMT | Report | CO | M6 | 30/03/18 |
D2.3 | Report on unmet needs of the stakeholders | WP2 | hDMT | Report | CO | M6 | 30/03/18 |
D2.4 | Report on vision workshop | WP2 | hDMT | Report | PU | M12 | 27/09/18 report |
D2.5 | Report on strategy workshop | WP2 | hDMT | Report | PU | M18 | 30/03/19 report |
D2.6 | Roadmap | WP2 | hDMT | Report | PU | M24 | 19/07/19 report |
D3.1 | Societal and economic impact | WP3 | Fraunhofer | Report | PU | M10 | 31/07/18 report |
D3.2 | Current and future potential business models | WP3 | Fraunhofer | Report | PU | M18 | 30/03/19 report |
D3.3 | Questionnaire for stakeholders | WP3 | Fraunhofer | Report | PU | M15 | 21/12/18 report |
D3.4 | Identification of training needs | WP3 | Fraunhofer | Report | PU | M24 | 29/09/19 report |
D4.1 | Specifications for the digital platform | WP4 | CEA | Report | CO | M6 | 04/04/18 |
D4.2 | Digital platform | WP4 | CEA | Websites etc | PU | M12 | 28/09/18 report |
D4.3 | Report on pilot project | WP4 | CEA | Report | CO | M24 | 26/09/19 |
D5.1 | Report on state-of-the-art and SWOT analysis | WP5 | IMEC | Report | PU | M12 | 30/09/18 report |
D5.2 | Societal primer on ethical use and implications | WP5 | IMEC | Report | PU | M12 | 11/02/19 report |
D5.3 | Guideline for the research community | WP5 | IMEC | Report | PU | M16 | 11/02/19 report |
D5.4 | Organ-on-chip – outlook on the regulatory pathway | WP5 | IMEC | Report | PU | M20 | 31/05/19 report |
D5.5 | White paper on standardization | WP5 | IMEC | Report | PU | M16 | 31/01/19 report |
D5.6 | Policy paper on ethics, regulatory and standardization | WP5 | IMEC | Report | PU | M24 | 29/09/19 report |
D5.7 | Primer on organ-onchip – Desirable, safe & efficient | WP5 | IMEC | Report | PU | M24 | 29/09/19 report |
D5.8 | Organ-on-chip as next drug discovery route | WP5 | IMEC | Report | PU | M24 | 29/09/19 report |
D6.1 | Final dissemination plan | WP6 | UNIZAR | Report | PU | M3 | 28/12/17 report |
D6.2 | Intermediate report on dissemination and communication | WP6 | UNIZAR | Report | CO | M12 | 30/09/18 |
D6.3 | Final report on dissemination and communication | WP6 | UNIZAR | Report | CO | M24 | 30/09/19 |
D6.4 | Website and project logo | WP6 | UNIZAR | Websites etc | PU | M2 | 28/12/17 report |
Milestones
MS number | Milestone Title | WP Number | Lead | Due Date (M) | Achieved |
---|---|---|---|---|---|
MS1 | Acceptance of the midterm report | WP1 | LUMC | M13 | yes |
MS2 | Vision workshop | WP2 | hDMT | M9 | yes |
MS3 | Strategy workshop | WP2 | hDMT | M16 | yes |
MS4 | Roadmap release | WP2 | hDMT | M24 | yes |
MS5 | Impact study | WP3 | Fraunhofer | M10 | yes |
MS6 | Definition of required training and skill sets | WP3 | Fraunhofer | M24 | yes |
MS7 | Digital platform tested and ready to be launched | WP4 | CEA | M18 | yes |
MS8 | Digital platform accounting a minimum of 100 active members | WP4 | CEA | M24 | yes |
MS9 | Reach out of the white paper towards stakeholders and policy makers | WP5 | IMEC | M16 | yes |
MS10 | Acceptance of the status of Dissemination and Communication activities performed | WP6 | UNIZAR | M13 | yes |
MS11 | Increased awareness of the ORCHID network and organ-on-chip technology throughout the European Union | WP6 | UNIZAR | M24 | yes |
The consortium is composed of the following organizations:
Christine Mummery
Ellen Thomassen
Janny van den Eijnden – van Raaij
Peter Loskill
Xavier Gidrol
Nathalie Picollet D’hahan
Sylvie Millet
Fabrice Navarro
Remco Den Dulk
Wolfgang Eberle
Dries Braeken
Luis Fernandez
Ignacio Ochoa
Janny van den Eijnden – van Raaij
Mart Graef
Massimo Mastrangeli
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 766884
.
Prof. dr. Christine Mummery
Leiden University Medical Center (LUMC)
Postal Zone S1-P
P.O. Box 9600
2300 RC Leiden
The Netherlands
Ellen Thomassen
Leiden University Medical Center (LUMC)
Postal Zone S4-P
P.O. Box 9600
2300 RC Leiden
The Netherlands